|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Hadassah Medical Organization |
|---|---|
| Information provided by: | Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT00130741 |
Purpose
This is an 8-week double-blind, placebo-controlled, randomized, parallel-group study with an additional two week baseline observation period to evaluate the safety of combination herbal therapy (CHT) versus placebo and short and long-term efficacy in terms of improved IBS, overall quality of life (QOL) and symptomatology.
| Condition | Intervention | Phase |
|---|---|---|
|
Colonic Diseases, Functional |
Drug: CHT - herbal therapy |
Phase I |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Phase I, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of a Combination Herbal Therapy (CHT), Versus Placebo in Improving the Overall Quality of Life and Symptoms in Patients With Irritable Bowel Syndrome (IBS) |
| Estimated Enrollment: | 100 |
| Study Start Date: | July 2005 |
| Study Completion Date: | January 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of irritable bowel syndrome based on the following criteria (ROME II): At least 12 weeks, which need not be consecutive, in the preceding 12 months of abdominal discomfort or pain (at least once per week) with at least 2 of the following features:
At least two of the following on at least 25% of occasions or days in the last 3 months:
Exclusion Criteria:
Contacts and Locations
More Information
| ClinicalTrials.gov Identifier: | NCT00130741 History of Changes |
| Other Study ID Numbers: | 391-14.1.05-HMO-CTIL |
| Study First Received: | August 15, 2005 |
| Last Updated: | April 10, 2007 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
Colonic Diseases Colonic Diseases, Functional Irritable Bowel Syndrome |
Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |